Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Indrasish Podder

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Indian Dermatology Online Journal|January 29, 2024
Analyzing and Utilizing Artificial Intelligence-Generated ContentsHimel Mondal, Shaikat Mondal, Indrasish Podder
Indian Journal of Dermatology|February 21, 2017
Interdepartmental Dermatology: Characteristics and Impact of Dermatology Inpatient Referrals at a Teaching Hospital in Eastern IndiaSatyendra Nath Chowdhury, Indrasish Podder, Abanti Saha, et al.
Cureus|June 13, 2024
Efficacy and Safety of Amorolfine Lotion 0.25% w/v Compared to Amorolfine Cream 0.25% w/w in Patients With Superficial Fungal Infections of the Skin: A Multi-center, Randomized, Open-Label, Active-Controlled, Non-inferiority Phase III Clinical TrialM Kanaka Prasad Rao, Lokesh Siddananjappa, Neetu Sidana, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Indian Dermatology Online Journal|January 29, 2024
Analyzing and Utilizing Artificial Intelligence-Generated ContentsHimel Mondal, Shaikat Mondal, Indrasish Podder
Indian Journal of Dermatology|February 21, 2017
Interdepartmental Dermatology: Characteristics and Impact of Dermatology Inpatient Referrals at a Teaching Hospital in Eastern IndiaSatyendra Nath Chowdhury, Indrasish Podder, Abanti Saha, et al.
Cureus|June 13, 2024
Efficacy and Safety of Amorolfine Lotion 0.25% w/v Compared to Amorolfine Cream 0.25% w/w in Patients With Superficial Fungal Infections of the Skin: A Multi-center, Randomized, Open-Label, Active-Controlled, Non-inferiority Phase III Clinical TrialM Kanaka Prasad Rao, Lokesh Siddananjappa, Neetu Sidana, et al.
Pageof 1